Summary
In 2025, biotechnology stocks significantly outperformed the broader market after years of underwhelming performance. The boost in biotech was driven by increased private investment, significant merger activities, and the growing need for age-related treatments due to a rising elderly population.
Key Facts
- Biotech stock indexes returned between 28% and 36% in 2025, while the S&P 500 returned about 18%.
- Private investment in longevity research doubled in 2025, reaching $8.49 billion.
- The FDA approved 50 new drugs in 2024 and 46 in 2025, with some aimed at increasing lifespan.
- Big pharmaceutical companies spent over $65 billion acquiring biotech firms by October 2025.
- The global population aged 60 and older is expected to reach 1.4 billion by 2030, with those aged 80 and older nearly tripling by 2050.
- Clinical-stage biotech stocks saw the highest returns, with some funds gaining almost 64%.
- Biopharma companies face a patent cliff, risking over $300 billion in branded drug revenue due to upcoming patent expirations.
